Revance is setting the new standard in healthcare by elevating patient and physician experiences through the development, acquisition and commercialization of innovative aesthetic and …

2020年3月24日 · Revance Aesthetics is building the prestige market for aesthetics comprised of expertly created products and services that are available exclusively in select practices that …

Revance is building a prestige aesthetics category with our lead investigational candidate DaxibotulinumtoxinA for Injection, RHA® Collection and HintMD.

2024年1月26日 · Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and …

Revance’s therapeutic pipeline seeks to bring innovation to multiple indications in muscle movement and pain disorders.

Following completion of the Offer, Crown completed the acquisition of Revance through the previously-planned and announced second-step merger. Revance’s common stock will be …

In November 2020, Revance announced results from a Phase 2 clinical trial evaluating DAXXIFY® for Injection for the management of plantar fasciitis. Revance plans to analyze the …

In partnership with Viatris Inc. (formerly known as Mylan N.V.), Revance is developing a biosimilar to BOTOX®, which would allow Revance to compete in the existing short-acting …

We are always looking for great talent to join Revance. Explore career opportunities below in finance, R&D, science, and more. Revance is headquartered in Nashville, Tenn., with …

Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results